Policy Updates on Access to and Affordability of Innovative Medicines in China.
暂无分享，去创建一个
[1] Jing Sun,et al. Unlocking Access To Novel Medicines In China-A Review From A Health System Perspective , 2019, Risk management and healthcare policy.
[2] Fernando Antonanzas,et al. The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments , 2019, PharmacoEconomics.
[3] Lili Xu,et al. Reforming China's drug regulatory system , 2018, Nature Reviews Drug Discovery.
[4] Jing Wu,et al. Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions. , 2018, Value in health regional issues.
[5] Gordon Liu,et al. China's Health Reform Update. , 2017, Annual review of public health.
[6] Si Jin,et al. The availability and affordability of orphan drugs for rare diseases in China , 2016, Orphanet Journal of Rare Diseases.
[7] Hao Yu. Universal health insurance coverage for 1.3 billion people: What accounts for China's success? , 2015, Health Policy.
[8] L. Garrison,et al. Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers , 2014, Applied Health Economics and Health Policy.
[9] Q. Meng,et al. Pharmaceutical policy in China. , 2008, Health affairs.
[10] C. Lucas. Dying to survive and cancer care in China. , 2019, The Lancet. Oncology.